154039-60-8 | Marimastat

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$42.00	$29.00
5mg	98%	in stock	$92.00	$64.00
25mg	98%	in stock	$270.00	$189.00
50mg	98%	in stock	$405.00	$283.00
100mg	98%	in stock	$608.00	$425.00
250mg	98%	in stock	$910.00	$637.00

Description

• Catalog Number: AD70178
• Chemical Name: Marimastat
• CAS Number: 154039-60-8
• Molecular Formula: C15H29N3O5
• Molecular Weight: 331.4079
• MDL Number: MFCD00866242
• SMILES: ONC(=O)[C@H]([C@H](C(=O)N[C@@H](C(C)(C)C)C(=O)NC)CC(C)C)O

Computed Properties

• Complexity: 431
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 23
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 5
• Rotatable Bond Count: 8
• XLogP3: 0.5

Literature

• Hypoxia suppresses E-cadherin and enhances matrix metalloproteinase-2 expression favoring esophageal carcinoma migration and invasion via hypoxia inducible factor-1 alpha activation.

  Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20130101

• Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells.

  American journal of physiology. Gastrointestinal and liver physiology 20120701

• Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis.

  Cancer metastasis reviews 20120601

• Biochemical characterization and N-terminomics analysis of leukolysin, the membrane-type 6 matrix metalloprotease (MMP25): chemokine and vimentin cleavages enhance cell migration and macrophage phagocytic activities.

  The Journal of biological chemistry 20120413

• Matrix metalloproteinase-9 in a unique proteoglycan form in avian embryonic growth plate cartilage.

  Archives of biochemistry and biophysics 20120401

• Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.

  Cancer 20120315

• Biochemical analysis of matrix metalloproteinase activation of chemokines CCL15 and CCL23 and increased glycosaminoglycan binding of CCL16.

  The Journal of biological chemistry 20120217

• Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections.

  PLoS pathogens 20120201

• Labeling and enrichment of Arabidopsis thaliana matrix metalloproteases using an active-site directed, marimastat-based photoreactive probe.

  Bioorganic & medicinal chemistry 20120115

• A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer.

  Journal of clinical bioinformatics 20120101

• Interleukin-1 stimulates ADAM17 through a mechanism independent of its cytoplasmic domain or phosphorylation at threonine 735.

  PloS one 20120101

• Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis.

  PloS one 20120101

• EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression.

  BMC cancer 20120101

• Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer.

  PloS one 20120101

• Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

  EXS 20120101

• Current knowledge on pancreatic cancer.

  Frontiers in oncology 20120101

• Stroma targeting nuclear imaging and radiopharmaceuticals.

  International journal of molecular imaging 20120101

• Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis.

  The Journal of biological chemistry 20110930

• EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease.

  The American journal of pathology 20110901

• Log-scale dose response of inhibitors on a chip.

  Analytical chemistry 20110815

• An understanding of the genetic basis of asthma.

  The Indian journal of medical research 20110801

• PI3Kinase signaling in glioblastoma.

  Journal of neuro-oncology 20110701

• Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110701

• Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20110401

• Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor.

  Journal of immunology (Baltimore, Md. : 1950) 20110315

• Targeted therapies for metastatic esophagogastric cancer.

  Current treatment options in oncology 20110301

• EGFR gene overexpression retained in an invasive xenograft model by solid orthotopic transplantation of human glioblastoma multiforme into nude mice.

  Cancer investigation 20110301

• Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer.

  Disease models & mechanisms 20110301

• Extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) as a novel regulator of myogenic cell differentiation.

  Journal of cellular physiology 20110101

• New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

  Biochemistry research international 20110101

• Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.

  Biochemistry research international 20110101

• Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts.

  BMC cancer 20110101

• Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors.

  Journal of pharmacological and toxicological methods 20110101

• A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.

  Journal of hematology & oncology 20110101

• Molecular characteristics of pancreatic ductal adenocarcinoma.

  Pathology research international 20110101

• The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China.

  BMC medical research methodology 20110101

• Zinc-chelation contributes to the anti-angiogenic effect of ellagic acid on inhibiting MMP-2 activity, cell migration and tube formation.

  PloS one 20110101

• Promising molecular targeted therapies in breast cancer.

  Indian journal of pharmacology 20110101

• Latest developments and emerging treatment options in the management of stomach cancer.

  Cancer management and research 20110101

• HIF-1α effects on angiogenic potential in human small cell lung carcinoma.

  Journal of experimental & clinical cancer research : CR 20110101

• Current immunotherapeutic approaches in pancreatic cancer.

  Clinical & developmental immunology 20110101

• Long-Term Relapse-Free Survival by Interdisciplinary Collaboration in a Patient with Metastatic Pancreatic Cancer (UICC IV).

  Case reports in oncology 20110101

• Quantitative analysis of the effect of cancer invasiveness and collagen concentration on 3D matrix remodeling.

  PloS one 20110101

• Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice.

  PloS one 20110101

• Insights into the complex formed by matrix metalloproteinase-2 and alloxan inhibitors: molecular dynamics simulations and free energy calculations.

  PloS one 20110101

• Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.

  International journal of molecular sciences 20110101

• Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.

  Clinical Medicine Insights. Oncology 20110101

• Mining the Active Proteome of Arabidopsis thaliana.

  Frontiers in plant science 20110101

• A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.

  Neuro-oncology 20101101

• TGF-β signaling in gingival fibroblast-epithelial interaction.

  Journal of dental research 20101101

• Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer.

  Cancer research 20101001

• Matrix remodeling as stem cell recruitment event: a novel in vitro model for homing of human bone marrow stromal cells to the site of injury shows crucial role of extracellular collagen matrix.

  Matrix biology : journal of the International Society for Matrix Biology 20101001

• Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall.

  Acta neuropathologica 20100801

• Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.

  Neuroscience 20100630

• A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.

  British journal of cancer 20100629

• Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.

  Journal of mammary gland biology and neoplasia 20100601

• A statistics-based platform for quantitative N-terminome analysis and identification of protease cleavage products.

  Molecular & cellular proteomics : MCP 20100501

• Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury.

  Pediatric research 20100301

• Angiogenesis: Future of pharmacological modulation.

  Indian journal of pharmacology 20100201

• An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510.

  Biochemical and biophysical research communications 20100108

• Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck.

  Journal of biomedical science 20100101

• Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells.

  BMC cancer 20100101

• Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice.

  PloS one 20100101

• Angiogenesis and progression in human melanoma.

  Dermatology research and practice 20100101

• Current and emerging therapies for the treatment of pancreatic cancer.

  OncoTargets and therapy 20100101

• Metalloproteinase inhibitors: status and scope from marine organisms.

  Biochemistry research international 20100101

• Cytogenetic analysis of the pathology of frozen shoulder.

  International journal of shoulder surgery 20100101

• The role of funding and policies on innovation in cancer drug development.

  Ecancermedicalscience 20100101

• Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.

  Acta orthopaedica 20091204

• Integrin alpha(v)beta(3), metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect.

  Cellular signalling 20091201

• Hydroxamates: relationships between structure and plasma stability.

  Journal of medicinal chemistry 20091112

• Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors.

  The Journal of biological chemistry 20090904

• Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

  British journal of cancer 20090818

• In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts.

  ORL; journal for oto-rhino-laryngology and its related specialties 20090801

• Novel investigational drugs for gastric cancer.

  Expert opinion on investigational drugs 20090701

• Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects.

  Marine drugs 20090601

• Characterization of the catalytic activity of the membrane-anchored metalloproteinase ADAM15 in cell-based assays.

  The Biochemical journal 20090428

• Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child.

  The Journal of craniofacial surgery 20090301

• Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review.

  Medical science monitor : international medical journal of experimental and clinical research 20090201

• Current perspective of TACE inhibitors: a review.

  Bioorganic & medicinal chemistry 20090115

• Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice.

  BMC musculoskeletal disorders 20090101

• Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.

  Journal of hematology & oncology 20090101

• Stereotactic radiosurgery for glioblastoma: retrospective analysis.

  Radiation oncology (London, England) 20090101

• Risedronate inhibits human osteosarcoma cell invasion.

  Journal of experimental & clinical cancer research : CR 20090101

• Chronic obstructive pulmonary disease: towards pharmacogenetics.

  Genome medicine 20090101

• Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.

  Core evidence 20090101

• Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations.

  Cancer management and research 20090101

• Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.

  Journal of the National Cancer Institute 20081217

• Modelling prognostic factors in advanced pancreatic cancer.

  British journal of cancer 20080916

• A critical role for matrix metalloproteinases in liver regeneration.

  The Journal of surgical research 20080401

• Characterization of an exosite binding inhibitor of matrix metalloproteinase 13.

  Protein science : a publication of the Protein Society 20080101

• Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas.

  Cerebrospinal fluid research 20080101

• Experimental models of abdominal aortic aneurysms: an overview.

  Current pharmaceutical design 20080101

• Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

  BMC cancer 20080101

• Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains.

  Journal of molecular biology 20071102

• Diffuse glioma growth: a guerilla war.

  Acta neuropathologica 20071101

• Future therapeutic treatment of COPD: struggle between oxidants and cytokines.

  International journal of chronic obstructive pulmonary disease 20070901

• MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells.

  British journal of cancer 20070806

• Canadian recommendations for the treatment of glioblastoma multiforme.

  Current oncology (Toronto, Ont.) 20070601

• A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.

  British journal of cancer 20070507

• Molecular tools for metalloprotease sub-proteome generation.

  Journal of biotechnology 20070430

• Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators.

  Toxicon : official journal of the International Society on Toxinology 20070401

• Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat.

  European journal of pharmacology 20070315

• Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat.

  Journal of inorganic biochemistry 20070301

• Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20070101

• Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.

  Cancer research 20070101

• High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis.

  Arthritis research & therapy 20070101

• Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.

  BMC cancer 20070101

• Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.

  Arthritis research & therapy 20070101

• Proteinases in the joint: clinical relevance of proteinases in joint destruction.

  Arthritis research & therapy 20070101

• Breast tumour angiogenesis.

  Breast cancer research : BCR 20070101

• Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model.

  American journal of physiology. Gastrointestinal and liver physiology 20061201

• Role of erlotinib in the management of pancreatic cancer.

  Therapeutics and clinical risk management 20061201

• Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

  Journal of neuro-oncology 20061001

• Biological targets for therapeutic interventions in COPD: clinical potential.

  International journal of chronic obstructive pulmonary disease 20060901

• Temozolomide chemotherapy in patients with recurrent malignant gliomas.

  Journal of Korean medical science 20060801

• Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

  Journal of neuro-oncology 20060701

• Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.

  British journal of cancer 20060424

• Towards third generation matrix metalloproteinase inhibitors for cancer therapy.

  British journal of cancer 20060410

• Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

  British journal of cancer 20060327

• Anti-angiogenesis therapy in pancreatic carcinoma.

  JOP : Journal of the pancreas 20060309

• The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.

  Cardiovascular research 20060215

• TNF-alpha as a target for anti-asthma therapy.

  Clinical science (London, England : 1979) 20060201

• Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196.

  Clinical breast cancer 20060201

• Gastric cancer. Treatment of advanced disease and new drugs.

  Frontiers in bioscience : a journal and virtual library 20050901

• [Role of extracellular matrix degradation enzyme for glioma invasion].

  Nihon rinsho. Japanese journal of clinical medicine 20050901

• [Inhibition of cellular adhesion and invasion in gliomas].

  Nihon rinsho. Japanese journal of clinical medicine 20050901

• [Research on the antimetastatic agents].

  Nihon rinsho. Japanese journal of clinical medicine 20050901

• [Anti-angiogenesis treatment for brain tumors--present and future].

  Nihon rinsho. Japanese journal of clinical medicine 20050901

• Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases.

  Experimental cell research 20050715

• Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050615

• The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity.

  Toxicology and applied pharmacology 20050601

• Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050501

• Matrix metalloproteinase inhibition impairs the processing, formation and mineralization of dental tissues during mouse molar development.

  Experimental cell research 20050401

• Docetaxel in the management of advanced pancreatic cancer.

  Seminars in oncology 20050401

• Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.

  Cancer letters 20050310

• Epidermal growth factor receptor-dependent and -independent pathways in hydrogen peroxide-induced mitogen-activated protein kinase activation in cardiomyocytes and heart fibroblasts.

  The Journal of pharmacology and experimental therapeutics 20050301

• Macrophage elastase (MMP-12): a pro-inflammatory mediator?

  Memorias do Instituto Oswaldo Cruz 20050301

• Decreased production of collagen Type III in cultured smooth muscle cells from varicose vein patients is due to a degradation by MMPs: possible implication of MMP-3.

  Journal of vascular research 20050101

• A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma.

  HPB : the official journal of the International Hepato Pancreato Biliary Association 20050101

• ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage.

  The Journal of biological chemistry 20041203

• Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041201

• Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.

  British journal of cancer 20041101

• Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.

  British journal of cancer 20041018

• Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness.

  Expert review of anticancer therapy 20041001

• SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.

  Cancer research 20040901

• Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.

  British journal of cancer 20040705

• Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera.

  British journal of cancer 20040405

• Involvement of matrix metalloproteinases in the onset of dentin mineralization.

  European journal of oral sciences 20040401

• Novel therapies for pancreatic adenocarcinoma.

  Current gastroenterology reports 20040401

• ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.

  British journal of cancer 20040308

• Matrix metalloproteinase inhibitors.

  Current oncology reports 20040301

• A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours.

  British journal of cancer 20040223

• Crystal structure of the catalytic domain of human ADAM33.

  Journal of molecular biology 20040102

• Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?

  Breast cancer research : BCR 20040101

• Synthesis of marimastat and a marimastat conjugate for affinity chromatography and surface plasmon resonance studies.

  Bioconjugate chemistry 20040101

• [Expression of matrix metalloproteinases in patients with malignant tumors].

  Medicina (Kaunas, Lithuania) 20040101

• Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20031201

• Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid.

  Journal of periodontal research 20031201

• Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.

  British journal of cancer 20031006

• [Angiogenesis and metastasis in colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.

  Journal of medicinal chemistry 20030828

• Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.

  Bioorganic & medicinal chemistry letters 20030818

• Angiogenesis inhibitors under study for the treatment of lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.

  Medical science monitor : international medical journal of experimental and clinical research 20030801

• Anti-angiogenesis in cancer therapy.

  Seminars in oncology nursing 20030801

• In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds.

  The American journal of pathology 20030701

• Functional characterization of adherent synovial fluid cells in rheumatoid arthritis: destructive potential in vitro and in vivo.

  Arthritis and rheumatism 20030701

• The interaction of metal ions and Marimastat with matrix metalloproteinase 9.

  Journal of inorganic biochemistry 20030601

• Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats.

  Arthritis and rheumatism 20030601

• Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura.

  British journal of cancer 20030519

• Emerging drugs for non-small cell lung cancer.

  Expert opinion on emerging drugs 20030501

• Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy.

  British journal of cancer 20030422

• Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer.

  Cancer treatment reviews 20030401

• A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.

  International journal of oncology 20030201

• Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030201

• [Angiogenesis research--quo vadis?].

  Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 20030201

• Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.

  Anticancer research 20030101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20030101

• [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].

  Annales de biologie clinique 20030101

• Advances in molecular therapies in patients with brain tumors.

  Cancer control : journal of the Moffitt Cancer Center 20030101

• Drugs in development: bisphosphonates and metalloproteinase inhibitors.

  Arthritis research & therapy 20030101

• Marimastat: BB 2516, TA 2516.

  Drugs in R&D 20030101

• Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition.

  Clinical & experimental metastasis 20030101

• Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma.

  International journal of radiation oncology, biology, physics 20021201

• Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.

  Seminars in oncology 20021201

• Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021115

• Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group.

  Investigational new drugs 20021101

• Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.

  Cancer research 20021015

• Matrix metalloproteinase inhibition reduces adventitial thickening and collagen accumulation following balloon dilation.

  Cardiovascular research 20020901

• Matrix metalloproteinase inhibitor therapy to prevent complications as well as therapy for Ehler-Danlos syndrome.

  Medical hypotheses 20020901

• A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops.

  International journal of cancer 20020810

• Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta(3) receptor blockade.

  Atherosclerosis 20020801

• Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.

  Annals of surgical oncology 20020801

• A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020801

• Integrin alpha(v)beta6-associated ERK2 mediates MMP-9 secretion in colon cancer cells.

  British journal of cancer 20020729

• A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

  British journal of cancer 20020715

• Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration.

  Journal of vascular surgery 20020701

• Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice.

  Japanese journal of cancer research : Gann 20020701

• Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.

  British journal of cancer 20020617

• Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.

  Journal of medicinal chemistry 20020523

• [New drugs in bronchial cancer].

  Presse medicale (Paris, France : 1983) 20020511

• Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases.

  The Journal of biological chemistry 20020329

• Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.

  Cytokine 20020321

• [Progress in diagnosis and treatment of lung cancer].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20020320

• Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020301

• Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha.

  European journal of immunology 20020201

• Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer.

  Seminars in oncology 20020201

• Exploiting molecular targets in pancreatic cancer.

  Hematology/oncology clinics of North America 20020201

• Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells.

  International journal of cancer 20020110

• Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.

  Journal of medicinal chemistry 20020103

• Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor.

  Internal medicine journal 20020101

• Ectodomain shedding of cystinyl aminopeptidase from human placental membranes.

  Placenta 20020101

• Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model.

  Clinical & experimental metastasis 20020101

• The role of the matrix metalloproteinases during in vitro vessel formation.

  Angiogenesis 20020101

• Angiogenesis inhibitors in the treatment of lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20011201

• A phase II trial of marimastat in advanced pancreatic cancer.

  British journal of cancer 20011201

• Calmodulin inhibitors trigger the proteolytic processing of membrane type-1 matrix metalloproteinase, but not its shedding in glioblastoma cells.

  The Biochemical journal 20011015

• [Tumor dormancy therapy for hepatocellular carcinoma].

  Nihon rinsho. Japanese journal of clinical medicine 20011001

• Marimastat therapy as adjuvant to selective embolization in skeletal metastases of differentiated thyroid carcinoma.

  Clinical endocrinology 20010901

• Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.

  Journal of medicinal chemistry 20010802

• Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010801

• Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010801

• Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells.

  Journal of pediatric surgery 20010701

• Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.

  Bioorganic & medicinal chemistry letters 20010604

• [Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy].

  Nihon Geka Gakkai zasshi 20010501

• Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules.

  Journal of neuropathology and experimental neurology 20010401

• [Matrix metalloproteinase in human gastric carcinoma].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• [Matrix metalloproteinase inhibitors for therapy of cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer.

  Seminars in oncology 20010401

• Development of matrix metalloproteinase inhibitors in cancer therapy.

  Journal of the National Cancer Institute 20010207

• Angiogenesis: regulators and clinical applications.

  Biochemical pharmacology 20010201

• Oral matrix metalloproteinase inhibition and arterial remodeling after balloon dilation: an intravascular ultrasound study in the pig.

  Circulation 20010116

• Matrix metalloproteinases in lung biology.

  Respiratory research 20010101

• Therapeutic angiogenesis inhibitors in the treatment of cancer.

  Advances in internal medicine 20010101